Cargando…
Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
Recent studies have offered ample insight into genome-wide expression patterns to define pancreatic ductal adenocarcinoma (PDAC) subtypes, although there remains a lack of knowledge regarding the underlying epigenomics of PDAC. Here we perform multi-parametric integrative analyses of chromatin immun...
Autores principales: | Lomberk, Gwen, Blum, Yuna, Nicolle, Rémy, Nair, Asha, Gaonkar, Krutika Satish, Marisa, Laetitia, Mathison, Angela, Sun, Zhifu, Yan, Huihuang, Elarouci, Nabila, Armenoult, Lucile, Ayadi, Mira, Ordog, Tamas, Lee, Jeong-Heon, Oliver, Gavin, Klee, Eric, Moutardier, Vincent, Gayet, Odile, Bian, Benjamin, Duconseil, Pauline, Gilabert, Marine, Bigonnet, Martin, Garcia, Stephane, Turrini, Olivier, Delpero, Jean-Robert, Giovannini, Marc, Grandval, Philippe, Gasmi, Mohamed, Secq, Veronique, De Reyniès, Aurélien, Dusetti, Nelson, Iovanna, Juan, Urrutia, Raul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958058/ https://www.ncbi.nlm.nih.gov/pubmed/29773832 http://dx.doi.org/10.1038/s41467-018-04383-6 |
Ejemplares similares
-
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT
por: Barraud, Marine, et al.
Publicado: (2016) -
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer
por: Nicolle, Rémy, et al.
Publicado: (2020) -
Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
por: Nicolle, Rémy, et al.
Publicado: (2017) -
Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
por: Bian, Benjamin, et al.
Publicado: (2017) -
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma
por: Molejon, Maria Inés, et al.
Publicado: (2015)